# 6 CCR 1007-1 Part 07: RADIATION CONTROL - USE OF RADIONUCLIDES IN THE HEALING ARTS

> Colorado · Regulations · In force

URL: https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_07

## Section

- **Citation:** 6 CCR 1007-1 Part 07
- **Heading:** RADIATION CONTROL - USE OF RADIONUCLIDES IN THE HEALING ARTS
- **Jurisdiction:** Colorado
- **Kind:** Regulations
- **Status:** In force
- **Text as of:** September 30, 2026
- **Source:** Compiled text
- **Location:** Code of Colorado Regulations / 1000 Department of Public Health and Environment / 1007 Hazardous Materials and Waste Management Division / 6 CCR 1007-1 Part 07

## Text

_________________________________________________________________________
Adopted by the Board of Health October 19, 2022, effective date December 15, 2022.
PART 7: USE OF RADIONUCLIDES IN THE HEALING ARTS
USE OF RADIONUCLIDES IN THE HEALING ARTS
Section A – General Information
7.1
Purpose and scope.
7.1.1
Authority
Rules and regulations set forth herein are adopted pursuant to the provisions of sections 25-1-
108, 25-1.5-101(1)(l), and 25-11-104, CRS.
7.1.2
Basis and Purpose.
A statement of basis and purpose accompanies this part and changes to this part. A copy may be
obtained from the Department.
7.1.3
Scope.
This part establishes requirements and provisions for the production, preparation, compounding
and use of radionuclides in the healing arts and for issuance of licenses authorizing the medical
use of this material. These requirements and provisions provide for the protection of the public
health and radiation safety of workers, the general public, patients, and human research subjects.
The requirements and provisions of this part are in addition to, and not in substitution for, others
in these regulations.
7.1.4
Applicability.
The requirements and provisions of these regulations apply to applicants and licensees subject to
this part unless specifically exempted.
7.1.5
Published material incorporated by reference.
7.1.5.1 Throughout this Part 7, federal regulations, state regulations, and standards or guidelines
of outside organizations have been adopted and incorporated by reference. Unless a
prior version of the incorporated material is otherwise specifically indicated, the materials
incorporated by reference cited herein include only those versions that were in effect as
of the most recent effective date of this Part 7 (December 15, 2022), and not later
amendments or editions of the incorporated material.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

2
7.1.5.2 Materials incorporated by reference are available for public inspection, and copies
(including certified copies) can be obtained at reasonable cost, during normal business
hours from the Colorado Department of Public Health and Environment, Hazardous
Materials and Waste Management Division, 4300 Cherry Creek Drive South, Denver,
Colorado 80246. Additionally, https://www.colorado.gov/cdphe/radregs identifies where
the incorporated federal and state regulations are available to the public on the internet at
no cost. A copy of the materials incorporated in this Part is available for public inspection
at the state publications depository and distribution center.
7.1.5.3 Availability from Source Agencies or Organizations.
(1)
All federal agency regulations incorporated by reference herein are available at
no cost in the online edition of the Code of Federal Regulations (CFR) hosted by
the U.S. Government Printing Office, online at www.govinfo.gov.
(2)
All state regulations incorporated by reference herein are available at no cost in
the online edition of the Code of Colorado Regulations (CCR) hosted by the
Colorado Secretary of State’s Office, online at
https://www.sos.state.co.us/CCR/RegisterHome.do.
(3)
Copies of the standards or guidelines of outside organizations are available
either at no cost or for purchase from the source organizations listed below.
a.
The Federal Policy for the Protection of Human Subjects: hhs.gov or
https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-
rule/index.html or
U.S. Department of Health & Human Services
200 Independence Avenue, S.W.
Washington, D.C.20201
Phone: 1-877-696-6775.
b.
NUREG-1556, Vol. 9: nrc.gov or https://www.nrc.gov/reading-rm/doc-
collections/nuregs/staff/sr1556/ or
U.S. Nuclear Regulatory Commission
Washington, DC 20555-0001
Phone: 1-800-368-5642.
7.2
Definitions.
As used in this part, these terms have the definitions set forth as follows:
“Address of use” means the building(s) identified on the license where radioactive material may
be produced, prepared, received, used or stored.
“Area of use” means a portion of an address of use that has been set aside for the purpose of
producing, preparing, receiving, using, or storing radioactive material.
“Associate Radiation Safety Officer” means, for the purposes of Part 7, an individual who:
(1)
Meets the requirements in Appendix 7A and 7.65; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

3
(2)
Is currently identified as an Associate Radiation Safety Officer for the types of
use of radioactive material for which the individual has been assigned duties and
tasks by the Radiation Safety Officer on:
a.
A specific medical use license issued by the Department, NRC or an
Agreement State;
b.
A medical use permit issued by an NRC master material licensee.
“Authorized medical physicist” (AMP) means an individual who meets the requirements of
Appendix 7B; or
(1)
Is identified as an authorized medical physicist or teletherapy physicist on:
a.
A specific medical use license issued by the Department, NRC, or
Agreement State;
b.
A medical use permit issued by an NRC master material licensee;
c.
A permit issued by an NRC or Agreement State broad scope medical
use licensee; or
d.
A permit issued by an NRC master material license broad scope medical
use permittee.
“Authorized nuclear pharmacist” (ANP) means a pharmacist who meets the requirements of
Appendix 7C; or
(1)
Is identified as an authorized nuclear pharmacist on:
a.
A specific license issued by the Department, NRC, or Agreement State
that authorizes medical use or the practice of nuclear pharmacy;
b.
A permit issued by an NRC master material licensee that authorizes
medical use or the practice of nuclear pharmacy;
c.
A permit issued by an NRC or Agreement State broad scope medical
use licensee that authorizes medical use or the practice of nuclear
pharmacy; or
d.
A permit issued by an NRC master material license broad scope medical
use permittee that authorizes medical use or the practice of nuclear
pharmacy; or
(2)
Is identified as an authorized nuclear pharmacist by a commercial nuclear
pharmacy that has been authorized to identify authorized nuclear pharmacists; or
(3)
Is designated as an authorized nuclear pharmacist in accordance with Part 3.
“Authorized user” (AU) means a physician, dentist, or podiatrist who meets the applicable
requirements of Appendix 7D through Appendix 7M; or
(1)
Is identified as an authorized user on:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

4
a.
A Department, NRC, or Agreement State license that authorizes the
medical use of radioactive material;
b.
A permit issued by an NRC master material licensee that is authorized to
permit the medical use of radioactive material;
c.
A permit issued by an NRC or Agreement State specific licensee of
broad scope that is authorized to permit the medical use of radioactive
material; or
d.
A permit issued by an NRC master material license broad scope
permittee that is authorized to permit the medical use of radioactive
material.
“Brachytherapy” means a method of radiation therapy in which plated, embedded, activated, or
sealed sources are utilized to deliver a radiation dose at a distance of up to a few centimeters, by
surface, intracavitary, intraluminal or interstitial application.
“Brachytherapy source” means a radioactive source or a manufacturer-assembled source train or
a combination of these sources that is designed to deliver a therapeutic dose within a distance of
a few centimeters.
“Client” means, for mobile medical service, the person for whom, or in conjunction with whom,
medical service is provided.
“Client's address” means the address of use for the purpose of providing mobile medical service
in accordance with 7.27.
“Dedicated check source” means a radioactive source that is used to assure the consistent
response of a radiation detection or measurement device over several months or years.
“Dentist” means an individual licensed by a State or Territory of the United States, the District of
Columbia or the Commonwealth of Puerto Rico to practice dentistry.
“Diagnostic clinical procedures manual” means a collection of written procedures that describes
each method (and other instructions and precautions) by which the licensee performs diagnostic
clinical procedures; where each diagnostic clinical procedure has been approved by the
authorized user and includes the radiopharmaceutical, dosage, and route of administration, or in
the case of sealed sources for diagnosis, the procedure.
“HDR”, see high dose-rate remote afterloader.
“High dose-rate remote afterloader” (HDR) means a device that remotely delivers a dose rate in
excess of 12 gray (1200 rad) per hour at the treatment site.
“LDR”, see low dose-rate remote afterloader.
“Low dose-rate remote afterloader” (LDR) means a device that remotely delivers a dose rate of
less than or equal to 2 gray (200 rad) per hour at the treatment site (at the specified distance).
“Management” means the chief executive officer, or other individual having the authority to
manage, direct, or administer the licensee's activities, or such person's' delegate(s).
“Manual brachytherapy” means a type of therapy in which brachytherapy sources are manually
applied or inserted.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

5
“MDR”, see medium dose-rate remote afterloader”.
“Medical institution” means an organization in which two or more medical disciplines are
practiced.
“Medical event” means an event that meets the criteria in 7.21.1 or 7.21.2.
“Medical use” means, for the purposes of Part 7, the intentional internal or external administration
of radioactive material or the radiation from radioactive material to patients or human research
subjects under the supervision of an authorized user.
“Medium dose-rate remote afterloader” (MDR) means a brachytherapy device that remotely
delivers a dose rate of greater than 2 gray (200 rads) per hour, but less than, or equal to 12 gray
(1200 rads) per hour at the point or surface where the dose is prescribed.
“Mobile medical service” means the transportation of radioactive material to, or its medical use at,
the client’s address and/or a temporary job site.
“Nuclear medicine technologist” (NMT) means an individual who meets the requirements of
Appendix 7N and who under the supervision of an authorized user prepares or administers
radioactive drugs to patients or human research subjects, or performs in vivo or in vitro
measurements for medical purposes.
“Nuclear medicine technology” means the science and art of in vivo and in vitro detection and
measurement of radioactivity and the administration of radioactive drugs to patients or human
research subjects for diagnostic and therapeutic purposes.
“Ophthalmic physicist” means an individual who:
(1)
Meets the requirements in 7.41.6.1(2) and 7.65; and
(2)
Is identified as an ophthalmic physicist on a:
a.
Specific medical use license issued by the Department, NRC or an
Agreement State;
b.
Permit issued by the Department, NRC or Agreement State broad scope
medical use licensee;
c.
Medical use permit issued by a NRC master material licensee; or
d.
Permit issued by a NRC master material license broad scope medical
use permittee.
“Output” means the exposure rate, dose rate, or a quantity related in a known manner to these
rates, from a brachytherapy source, or a teletherapy, remote afterloader, or gamma stereotactic
radiosurgery unit, for a specified set of exposure conditions.
“Patient intervention” means actions by the patient or human research subject, whether
intentional or unintentional, such as dislodging or removing treatment devices or prematurely
terminating the administration.
“PDR”, see pulsed dose-rate remote afterloader.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

6
“Pharmacist” means an individual licensed by a State or Territory of the United States, the District
of Columbia or the Commonwealth of Puerto Rico to practice pharmacy. (See also Authorized
nuclear pharmacist)
“Physician” means an individual licensed by a State or Territory of the United States, the District
of Columbia or the Commonwealth of Puerto Rico to prescribe drugs in the practice of medicine.
“Podiatrist” means an individual licensed by a State or Territory of the United States, the District
of Columbia or the Commonwealth of Puerto Rico to practice podiatry.
“Preceptor” means an individual who provides, directs or verifies training and experience required
for an individual to become an authorized user, an authorized medical physicist, an authorized
nuclear pharmacist, a Radiation Safety Officer, an Associate Radiation Safety Officer (see
appendices 7A through 7M, and 7P).
“Prescribed dosage” means the specified activity or range of activity of a radioactive drug as
documented in:
(1)
A written directive as specified in 7.11; or
(2)
Accordance with the directions of the authorized user for procedures performed
pursuant to 7.30, 7.32, or 7.36.
“Prescribed dose” means:
(1)
For gamma stereotactic radiosurgery, the total dose as documented in the written
directive;
(2)
For teletherapy, the total dose and dose per fraction as documented in the
written directive;
(3)
For manual brachytherapy, either the total source strength and exposure time or
the total dose, as documented in the written directive; or
(4)
For remote brachytherapy afterloaders, the total dose and dose per fraction as
documented in the written directive.
“Pulsed dose-rate remote afterloader” (PDR) means a special type of remote afterloading device
that uses a single source capable of delivering dose rates (at the specified distance) in the “high
dose-rate” range, but:
(1)
Is approximately one-tenth of the activity of typical high dose-rate remote
afterloader sources; and
(2)
Is used to simulate the radiobiology of a low dose rate treatment by inserting the
source for a given fraction of each hour.
“Radiation safety officer” (RSO) means, for the purposes of Part 7, an individual who has
demonstrated sufficient knowledge to apply radiation protection regulations appropriately, who in
accord with 7.7 has been assigned such responsibility by the licensee, and who meets the
requirements in Appendix 7A; or
(1)
Is identified as a Radiation Safety Officer on:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

7
a.
A specific medical use license issued by the Department, NRC, or
Agreement State; or
b.
A medical use permit issued by an NRC master material licensee.
“Radioactive drug” means any chemical compound containing radioactive material that may be
used on or administered to patients or human research subjects as an aid in the diagnosis,
treatment, or prevention of disease or other abnormal condition.
“Sealed source” means radioactive material that is permanently bonded or fixed in a capsule or
matrix designed to prevent release and dispersal of the radioactive material under the most
severe conditions which are likely to be encountered in normal use and handling.
“Sealed Source and Device Registry” means the national registry that contains all the registration
certificates, generated by both the Nuclear Regulatory Commission and the Agreement States,
that summarize the radiation safety information for the sealed sources and devices and describe
the licensing and use conditions approved for the product.
“Stereotactic radiosurgery” means the use of external radiation in conjunction with a stereotactic
guidance device to precisely deliver a dose to a treatment site.
“Structured educational program” means an accredited educational program designed to impart
particular knowledge and practical education through interrelated studies and supervised training.
“Teletherapy”, as used in this part, means a method of radiation therapy in which collimated
gamma rays are delivered at a distance from the patient or human research subject.
“Temporary job site”, as used in Part 7, means a location where mobile medical services are
confined to the mobile unit not at a licensed address of use.
“Therapeutic dosage” means a dosage of unsealed radioactive material that is intended to deliver
a radiation dose to a patient or human research subject for palliative or curative treatment.
“Therapeutic dose” means a radiation dose delivered from a sealed source containing radioactive
material to a patient or human research subject for palliative or curative treatment.
“Treatment site” means the anatomical description of the tissue intended to receive a radiation
dose, as described in a written directive.
“Trunnion” means a support bar sometimes used as a bearing instead of a socket.
“Type of use” means use of radioactive material as specified under 7.30, 7.32, 7.36, 7.40, 7.42,
7.48 or 7.62.
“Unit dosage” means a dosage that:
(1)
Is obtained or prepared in accordance with the regulations for uses described in
7.30, 7.32, or 7.36; and
(2)
Is to be administered as a single dosage to a patient or human research subject
without any further manipulation of the dosage after it is initially prepared.
“Written directive” means an authorized user's written order for the administration of radioactive
material or radiation from radioactive material to a specific patient or human research subject, as
specified in 7.11.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

8
GENERAL REGULATORY REQUIREMENTS
7.3
License required.
7.3.1
7.3.1.1 A person may manufacture, produce, acquire, receive, possess, prepare, use, or transfer
radioactive material for medical use only in accordance with a specific license issued by
the Department, an Agreement State or NRC, or as allowed in 7.3.1.2.
7.3.1.2 A specific license is not needed for an individual who:
(1)
Receives, possess, uses, or transfers radioactive material in accordance with the
regulations under the supervision of an authorized user as provided in 7.10,
unless prohibited by license condition; or
(2)
Prepares unsealed radioactive material for medical use in accordance with the
regulations under the supervision of an authorized nuclear pharmacist or
authorized user as provided in 7.10, unless prohibited by license condition.
7.3.2
Provisions for the protection of Human Research Subjects.
A licensee may conduct research involving human subjects using radioactive material under the
following conditions:
7.3.2.1 For research conducted, funded, supported, or regulated by a federal agency which has
implemented The Federal Policy for the Protection of Human Subjects (Federal Policy),
the licensee shall:
(1)
Obtain prior informed consent from the human research subjects; and
(2)
Obtain prior review and approval of the research activities by an “Institutional
Review Board” in accordance with the meaning of these terms as defined and
described in the Federal Policy; or
7.3.2.2 For research not conducted, funded, supported, or regulated by a federal agency which
has implemented the Federal Policy, then:
(1)
The licensee shall apply for and receive a specific amendment to its Department
license before conducting such research. The amendment request shall include a
written commitment that the licensee will, before conducting research:
(a)
Obtain prior informed consent from the human research subjects; and
(b)
Obtain prior review and approval of the research activities by an
“Institutional Review Board” in accordance with the meaning of these
terms as defined and described in the Federal Policy;
7.3.2.3 A licensee not authorized pursuant to Part 3, Section 3.11 shall apply for and receive
approval of a specific amendment to its Department license before conducting research
involving human subjects;
7.3.2.4 The research involving human subjects authorized in 7.3.2 shall be conducted using
radioactive material authorized for medical use in the license; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

9
7.3.2.5 Nothing in 7.3.2 relieves licensees from complying with the other requirements in Part 7.
7.3.3
Nothing in this part relieves the licensee from complying with applicable FDA, other federal, and
state requirements governing radioactive drugs or devices.
7.3.4
Application for license, amendment, or renewal.
7.3.4.1 An application must be signed by the applicant's or licensee's management.
7.3.4.2 An application for a new or renewal license for medical use of radioactive material as
described in 7.30, 7.32, 7.36, 7.40, 7.42, 7.48 or 7.62 must be made by:
(1)
Filing an original Department Form R-12 (7C) that includes the facility diagram,
equipment, and training and experience qualifications of the Radiation Safety
Officer, Associate Radiation Safety Officer(s), authorized user(s), authorized
medical physicist(s), ophthalmic physicist(s), and authorized nuclear
pharmacist(s); and
(2)
Submitting procedures required by Form R-12 (7C), and 7.12, 7.15, 7.51, 7.58,
7.59, and 7.61, as applicable, and other procedures as requested by the
Department.
7.3.4.3 A request for a license amendment must be made by:
(1)
Submitting an original amendment request in letter format.
(2)
Submitting procedures required by 7.12, 7.15, 7.51, 7.58, 7.59, and 7.61, as
applicable, and other procedures as requested by the Department.
7.3.4.4 In addition to the requirements in 7.3.4.2 and 7.3.4.3, an application for a new license,
renewal license, or amendment for medical use of radioactive material as described in
7.62 must also include:
(1)
Any additional aspects of the medical use of the material that are applicable to
radiation safety that are not addressed in, or differ from:
(a)
Section A through C (7.1 through 7.29);
(b)
Sections D through H (recordkeeping requirements);
(c)
Section I (7.65);
(d)
Appendix 7A, 7B, 7C and 7P;
(2)
Identification of and commitment to follow the applicable radiation safety program
requirements in Sections D through H that are appropriate for the specific 7.62
medical use;
(3)
Any additional specific information on:
(a)
Radiation safety precautions and instructions;
(b)
Methodology for measurement of dosages or doses to be administered
to patients or human research subjects; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

10
(c)
Calibration, maintenance, and repair of instruments and equipment
necessary for radiation safety; and
(4)
Any other information requested by the Department in its review of the
application.
7.3.4.5 An applicant that satisfies the requirements specified in Part 3, Section 3.11 may apply
for a Type A specific license of broad scope.
7.3.5
Mobile Medical Service Administrative Requirements.
7.3.5.1 The Department shall license mobile medical services or clients of such services. The
mobile medical service shall be licensed if the service receives, uses or possesses
radioactive material. The client of the mobile medical service shall be licensed if the client
receives or possesses radioactive material to be used by a mobile medical service.
7.3.5.2 Mobile medical service licensees shall obtain a letter signed by the management of each
location where services are rendered that authorizes use of radioactive material at the
client's address of use. This letter shall clearly delineate the authority and responsibility of
both the client and the mobile medical service. If the client is licensed, the letter shall
document procedures for notification, receipt, storage and documentation of transfer of
radioactive material delivered to the client's address for use by the mobile medical
service.
7.3.5.3 A mobile medical service shall not have radioactive material delivered directly from the
manufacturer or the distributor to the client, unless the client has a license allowing
possession of the radioactive material. Radioactive material delivered to the client shall
be received and handled in conformance with the client's license.
7.3.5.4 A mobile medical service shall inform the client's management who is on site at each
client's address of use at the time that radioactive material is being administered.
7.3.5.5 A licensee providing mobile medical services shall retain the letter required in 7.3.5.2 for
3 years after the last provision of service.
7.3.5.6 A mobile medical service licensee shall, at a minimum, maintain the following documents
on each mobile unit:
(1)
The current operating and emergency procedures;
(2)
A copy of the license;
(3)
Copies of the letter required by 7.3.5.2;
(4)
Current calibration records for each survey instrument and diagnostic equipment
or dose delivery device in use; and
(5)
Survey records covering uses associated with the mobile unit during, at a
minimum, the preceding 30 calendar days.
7.3.5.7 The mobile medical service shall designate and manage each area of use in the client’s
facility as a restricted area while radioactive material is present. For each location where
radioactive materials will be routinely used, the licensee shall provide to the Department:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

11
(1)
A diagram of the location of use, including information about the placement of
required postings; and
(2)
Calculation(s) or survey(s) results that demonstrate compliance with applicable
dose limits in Part 4, Sections 4.14 and 4.15 at the location of use.
7.3.5.8 The mobile medical service shall ensure that:
(1)
Supervision by an authorized user is in accordance with 7.10.1;
(2)
Radiation exposures to the client’s personnel working in the client facility are:
(a)
Below the dose limits to members of the public listed in Part 4, Section
4.14; or
(b)
The client's personnel are instructed as described in Part 10, Section
10.3 and monitored for exposure in accordance with Part 4, Section 4.18
unless the licensee can demonstrate that Section 4.18 does not apply.
7.3.5.9 A mobile medical service licensee shall maintain all records required by Parts 4 and 7 of
these regulations at a location within the Department's jurisdiction that is:
(1)
A single address of use:
(a)
Identified as the records retention location; and
(b)
Staffed at all reasonable hours by individual(s) authorized to provide the
Department with access for purposes of inspection; or
(2)
When no address of use is identified on the license for records retention, the
mobile unit:
(a)
Identified in the license; and
(b)
Whose current client's address of use and area of use schedule is
reported to the Department.
7.3.6
A licensee possessing a Type A specific license of broad scope for medical use, issued under
Part 3 of these regulations, is exempt from:
7.3.6.1 The provisions of 7.3.4.4 regarding the need to file an amendment to the license for
medical uses of radioactive material as described in 7.62;
7.3.6.2 The provisions of 7.4.2 regarding the need to file an amendment before permitting
anyone to work as an authorized user, an authorized nuclear pharmacist or an authorized
medical physicist under the license;
7.3.6.3 The provisions of 7.4.5 regarding additions to or changes in the areas of use at the
addresses identified in the application or on the license;
7.3.6.4 The provisions of 7.5.1 regarding notification to the Department for new authorized users,
new authorized nuclear pharmacists and new authorized medical physicists;
7.3.6.5 The provisions of 7.5.2.1 for an authorized user, an authorized nuclear pharmacist, an
authorized medical physicist or an ophthalmic physicist;
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

12
7.3.6.6 The provisions of 7.5.2.5; and
7.3.6.7 The provisions of 7.14 regarding suppliers for sealed sources.
7.3.7
The Department may, upon application of any interested person or upon its own initiative, grant
such exemptions from the regulations in Part 7 as it determines are authorized by law and will not
endanger life or property or the physical protection of material and are otherwise in the public
interest.
7.4
License amendments.
A licensee shall apply for and must receive a license amendment:
7.4.1
Before it receives, prepares, or uses radioactive material for a type of use that is permitted under
this part but is not authorized on the licensee’s current license issued under this part;
7.4.2
Before it permits anyone to work as an authorized user, authorized medical physicist, ophthalmic
physicist, or an authorized nuclear pharmacist under the license, except:
7.4.2.1 For an authorized user, an individual who meets the requirements in Appendix 7P and
one or more of the following: Section 7D1 of Appendix D, Section 7E1 of Appendix E,
Section 7F1 of Appendix F, Section 7G1 of Appendix 7G, Section 7H1 of Appendix 7H,
Section 7K1 of Appendix K, Section 7J1 of Appendix J, or Section 7M1 of Appendix M;
7.4.2.2 For an authorized nuclear pharmacist, an individual who meets the requirements in
Section 7C1 of Appendix 7C and 7.65;
7.4.2.3 For an authorized medical physicist, an individual who meets the requirements in Section
7B1 of Appendix 7B and 7.65;
7.4.2.4 An individual who is identified as an authorized user, an authorized nuclear pharmacist,
authorized medical physicist, or an ophthalmic physicist:
(1)
On a NRC or Agreement State license or other equivalent permit or license
recognized by the Department that authorizes the use of radioactive material in
medical use or in the practice of nuclear pharmacy;
(2)
On a permit issued by a NRC or Agreement State specific license of broad scope
that is authorized to permit the use of radioactive material in medical use or in the
practice of nuclear pharmacy;
(3)
On a permit issued by a NRC master material licensee that is authorized to
permit the use of radioactive material in medical use or in the practice of nuclear
pharmacy; or
(4)
By a commercial nuclear pharmacy that has been authorized to identify
authorized nuclear pharmacists.
7.4.2.5 A physician, podiatrist, or dentist who used only accelerator-produced radioactive
materials, discrete sources of radium-226, or both, for medical uses or a nuclear
pharmacist who used only accelerator-produced radioactive materials in the practice of
nuclear pharmacy at a Government agency or Federally recognized Indian Tribe before
November 30, 2007 or at all other locations of use before August 8, 2009, or an earlier
date as noticed by the NRC, and for only those materials and uses performed before
these dates.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

13
7.4.3
Before it changes a Radiation Safety Officer, except as provided in 7.7.3;
7.4.4
Before it permits anyone to work as an Associate Radiation Safety Officer, or before the
Radiation Safety Officer assigns duties to an Associate Radiation Safety Officer that differ from
those for which this individual is authorized on the license;
7.4.5
Before it receives radioactive material in excess of the amount or in a different physical or
chemical form, or receives a different radionuclide than is authorized on the license;
7.4.6
Before it adds to or changes the areas of use identified in the application or on the license,
including areas used in accordance with either 7.30 or 7.32 if the change includes addition or
relocation of either an area where PET radionuclides are produced or a PET radioactive drug
delivery line from the PET radionuclide/PET radioactive drug production area. Other areas of use
where radioactive material is used only in accordance with either 7.30 or 7.32 are exempt;
7.4.7
Before it changes the address(es) of use identified in the application or on the license;
7.4.8
Before it changes statements, representations, and procedures which are incorporated into the
license; or
7.4.9
Before it releases licensed facilities for unrestricted use.
7.4.10 Before it revises procedures required by 7.51, 7.58, 7.59, and 7.61, as applicable, where such
revision reduces radiation safety; and
7.4.11 Before it receives a sealed source from a different manufacturer or of a different model number
than authorized by its license unless the sealed source is used for manual brachytherapy, is listed
in the Sealed Source and Device Registry, and is in a quantity and for an isotope authorized by
the license.
7.5
Notifications and maintenance of records.
7.5.1
A licensee shall provide the Department, no later than 30 days after the date that the licensee
permits an individual to work under the provisions of 7.4.2 as an authorized user, authorized
medical physicist, ophthalmic physicist, or authorized nuclear pharmacist:
7.5.1.1 A copy of the board certification and, as appropriate, verification of completion of:
(1)
Training for the authorized medical physicist under 7B3 of Appendix 7B;
(2)
Any additional case experience required in 7F2.1(2)(f) of Appendix 7F for an
authorized user under 7.36; or
(3)
Device specific training in 7M3 of Appendix 7M for the authorized user under
7.48; or
7.5.1.2 A copy of the Department, NRC or Agreement State license, the permit issued by a NRC
master material licensee, the permit issued by a NRC or Agreement State licensee of
broad scope, the permit issued by a NRC master material license broad scope permittee,
or documentation that only accelerator-produced radioactive materials, discrete sources
of radium-226, or both, were used for medical use or in the practice of nuclear pharmacy
at a Government agency or Federally recognized Indian Tribe before November 30,
2007, or at all other locations of use before August 8, 2009, or an earlier date as noticed
by the NRC for each individual whom the licensee permits to work under the provisions of
this section.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

14
7.5.2
A licensee shall notify the Department in writing no later than 30 days after:
7.5.2.1 An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, an
Associate Radiation Safety Officer, an authorized medical physicist, or ophthalmic
physicist permanently discontinues performance of duties under the license or has a
name change;
7.5.2.2 The licensee permits an individual qualified to be a Radiation Safety Officer under
Appendix 7A and 7.65 to function as a temporary Radiation Safety Officer and to perform
the functions of a Radiation Safety Officer in accordance with 7.7.6.
7.5.2.3 The licensee's mailing address changes;
7.5.2.4 The licensee's name changes, but the name change does not constitute a transfer of
control of the license as described in Part 3, Section 3.15.2 of these regulations; or
7.5.2.5 The licensee has added to or changed the areas of use identified in the application or on
the license where radioactive material is used in accordance with either 7.30 or 7.32 if the
change does not include addition or relocation of either an area where PET radionuclides
are produced or a PET radioactive drug delivery line from the PET radionuclide/PET
radioactive drug production area; or
7.5.2.6 The licensee obtains a sealed source for use in manual brachytherapy from a different
manufacturer or with a different model number than authorized by its license for which it
did not require a license amendment as provided in 7.4.11. The notification must include
the manufacturer and model number of the sealed source, the isotope, and the quantity
per sealed source.
7.5.3
The licensee shall submit the documents required in 7.5.1 and 7.5.2 to the Department.
7.5.4
Maintenance of Records.
Each record required by this part must be legible throughout the retention period specified by
each Department regulation. The record may be the original, a reproduced copy, or a microform
provided that the copy or microform is authenticated by authorized personnel and the microform
is capable of producing a clear copy throughout the required retention period. The record may
also be stored in electronic media with the capability for producing legible, accurate, and
complete records during the required retention period. Records such as letters, drawings, and
specifications must include all pertinent information such as stamps, initials, and signatures. The
licensee shall maintain adequate safeguards against tampering with and loss of records.
7.6
License issuance.
7.6.1
The Department shall issue a license for the medical use of radioactive material if:
7.6.1.1 The applicant has filed Department Form R-12 in accordance with the instructions in
7.3.4;
7.6.1.2 The applicant has paid any applicable fee;
7.6.1.3 The applicant meets the requirements of Part 3 of these regulations; and
7.6.1.4 The Department finds the applicant equipped and committed to observe the safety
standards established by the Department in these regulations for the protection of the
public health and safety.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

15
7.6.2
The Department shall issue a license for mobile services if the applicant:
7.6.2.1 Meets the requirements in 7.6.1, and in particular 7.3.5; and
7.6.2.2 Assures that individuals to whom radioactive drugs or radiation from implants containing
radioactive material will be administered may be released following treatment in
accordance with 7.26.
Section B – General Administrative Requirements
7.7
Authority and responsibilities for the radiation protection program
7.7.1
In addition to the radiation protection program requirements of Part 4, Section 4.5 of these
regulations, a licensee's management shall approve in writing:
7.7.1.1 Requests for license application, renewal, or amendments before submittal to the
Department;
7.7.1.2 Any individual before allowing that individual to work as an authorized user, authorized
nuclear pharmacist or authorized medical physicist; and
7.7.1.3 Radiation protection program changes that do not require a license amendment and are
permitted under 7.7.
7.7.2
A licensee’s management shall appoint a Radiation Safety Officer (RSO), who agrees in writing to
be responsible for implementing the radiation safety program. The licensee, through the RSO,
shall ensure that radiation safety activities are being performed in accordance with licensee-
approved procedures and regulatory requirements. A licensee’s management may appoint, in
writing, one or more Associate Radiation Safety Officers (ARSO) to support the RSO. The RSO,
with written agreement of the licensee’s management, must assign the specific duties and tasks
to each ARSO. These duties and tasks are restricted to the types of use for which the ARSO is
listed on a license. The RSO may delegate duties and tasks to the ARSO but shall not delegate
the authority or responsibilities for implementing the radiation protection program.
7.7.3
For up to 60 days each year, a licensee may permit an individual qualified to be a Radiation
Safety Officer, under Appendix 7A and 7.65, to function as a temporary Radiation Safety Officer
and to perform the functions of a Radiation Safety Officer, as provided in 7.7.6, if the licensee
takes the actions required in 7.7.2, 7.7.5, 7.7.6, and 7.7.7 and notifies the Department in
accordance with 7.5.2.
7.7.4
A licensee may simultaneously appoint more than one temporary Radiation Safety Officer in
accordance with 7.7.3, if needed to ensure that the licensee has a temporary Radiation Safety
Officer that satisfies the requirements to be a Radiation Safety Officer for each of the different
types of uses of radioactive material permitted by the license.
7.7.5
A licensee shall establish the authority, duties, and responsibilities of the Radiation Safety Officer
in writing.
7.7.6
A licensee shall provide the Radiation Safety Officer sufficient authority, organizational freedom,
time, resources, and management prerogative, to:
7.7.6.1 Identify radiation safety problems;
7.7.6.2 Initiate, recommend, or provide corrective actions;
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

16
7.7.6.3 Stop unsafe operations; and
7.7.6.4 Verify implementation of corrective actions.
7.7.7
A licensee shall retain a record of actions taken under 7.7.1, 7.7.2, and 7.7.5 as follows:
Records of authority and responsibilities for radiation protection programs.
7.7.7.1 A licensee shall retain a record of actions taken by the licensee's management in
accordance with 7.7.1 for 5 years. The record must include a summary of the actions
taken and a signature of licensee management.
7.7.7.2 The licensee shall retain a copy of both authority, duties, and responsibilities of the
Radiation Safety Officer as required by 7.7.5, and a signed copy of each Radiation Safety
Officer's agreement to be responsible for implementing the radiation safety program, as
required by 7.7.2, for the duration of the license. The records must include the signature
of the Radiation Safety Officer and licensee management.
7.7.7.3 For each Associate Radiation Safety Officer appointed under 7.7.2, the licensee shall
retain, for 5 years after the Associate Radiation Safety Officer is removed from the
license, a copy of the written document appointing the Associate Radiation Safety Officer
signed by the licensee's management.
7.8
Radiation safety committee.
7.8.1
Licensees that are authorized for one or more different types of radioactive material use under
7.36, 7.42, 7.48, or 7.62 shall establish a Radiation Safety Committee to oversee all uses of
radioactive material permitted by the license.
7.8.2
The Committee shall:
7.8.2.1 Include:
(1)
An authorized user of each type of use permitted by the license;
(2)
The Radiation Safety Officer
(3)
A representative of the nursing service
(4)
A representative of management who is neither an authorized user nor a
Radiation Safety Officer; and
(5)
Other members as the licensee deems appropriate.
7.8.2.2 Meet as necessary, but at a minimum shall meet at intervals not to exceed 6 months.
7.8.2.3 Maintain minutes of each meeting, including:
(1)
The date of the meeting;
(2)
Members present;
(3)
Members absent; and
(4)
Summary of deliberations and discussions.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

17
7.9
Radiation protection program changes.
7.9.1
A licensee may revise its radiation protection program without Department approval if:
7.9.1.1 The revision does not require an amendment under 7.4;
7.9.1.2 The revision is in compliance with the regulations and the license;
7.9.1.3 The revision has been reviewed and approved by the Radiation Safety Officer, licensee
management and licensee's Radiation Safety Committee (if applicable); and
7.9.1.4 The affected individuals are instructed on the revised program before the changes are
implemented.
7.9.2
A licensee shall retain a record of each change for 5 years, including
7.9.2.1 A copy of the old and new procedures;
7.9.2.2 The effective date of the change; and
7.9.2.2 The signature of the licensee management that reviewed and approved the change.
7.10
Supervision.
7.10.1 A licensee that permits the receipt, possession, use, or transfer of radioactive material by an
individual under the supervision of an authorized user as allowed by 7.3.1.2(1) shall:
7.10.1.1
In addition to the requirements of Part 10, Section 10.3 of these regulations,
instruct the supervised individual in the licensee's written radiation protection procedures,
written directive procedures, regulations of Part 7, and license conditions with respect to
the use of radioactive material; and
7.10.1.2
Require the supervised individual to follow the instructions of the supervising
authorized user for medical uses of radioactive material, written radiation protection
procedures, written directive procedures, regulations of Part 7, and license conditions
with respect to the medical use of radioactive material.
7.10.2 A licensee that permits the preparation of radioactive material for medical use by an individual
under the supervision of an authorized nuclear pharmacist or physician who is an authorized
user, as allowed by 7.3.1.2(2), shall:
7.10.2.1
In addition to the requirements of Part 10, Section 10.3, instruct the supervised
individual in the preparation of radioactive material for medical use, as appropriate to that
individual's use of radioactive material; and
7.10.2.2
Require the supervised individual to follow the instructions of the supervising
authorized user or authorized nuclear pharmacist regarding the preparation of radioactive
material for medical use, the written radiation protection procedures, the regulations of
Part 7, and license conditions.
7.10.3 Unless physical presence as described in other sections of Part 7 is required, a licensee who
permits supervised activities under 7.10.1 and 7.10.2 shall require an authorized user to be
immediately available by telephone within ten minutes to communicate with the supervised
individual, unless otherwise authorized by the Department with prior written approval.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

18
7.10.4 A licensee who permits supervised activities under 7.10.1 and 7.10.2 is responsible for the acts
and omissions of the supervising authorized user and supervised individual(s).
7.10.5 A licensee who permits supervised activities under 7.10.1 and 7.10.2 shall require that the
administration of radioactive material or radiation from radioactive material under the supervision
of an authorized user be performed only by:
7.10.5.1
A physician;
7.10.5.2
An individual who meets the requirements of Appendix 7B or 7N;
7.10.5.3
An individual in training in medical physics while under personal supervision of
an individual meeting the requirements of Appendix 7B;
7.10.5.4
An individual in training in nuclear medicine technology while under personal
supervision of an individual meeting the requirements of Appendix 7N; or
7.10.5.5
An individual otherwise authorized in writing by the Department, or through
license condition(s).
7.11
Written directives.
7.11.1 A written directive must be dated and signed by an authorized user, including the signatory's
printed or typed name, before the administration of:
7.11.1.1
I-131 sodium iodide greater than 1.11 MBq (30 µCi), or
7.11.1.2
Any therapeutic dosage of radioactive material, or
7.11.1.3
Any therapeutic dose of radiation from radioactive material.
If, because of the emergent nature of the patient’s condition, a delay in order to provide a
written directive would jeopardize the patient’s health, an oral directive is acceptable. The
information contained in the oral directive must be documented as soon as possible in
writing in the patient’s record. A written directive must be prepared within 48 hours of the
oral directive.
7.11.2 The written directive must contain the patient or human research subject's name and the
following:
7.11.2.1
For an administration of a dosage of radioactive drug containing radioactive
material, the name of the radioactive drug containing radioactive material, dosage, and
route of administration;
7.11.2.2
For gamma stereotactic radiosurgery, the total dose, treatment site, and values
for the target coordinate settings per treatment for each anatomically distinct treatment
site;
7.11.2.3
For teletherapy, the total dose, dose per fraction, number of fractions, and
treatment site;
7.11.2.4
For high dose rate remote afterloading brachytherapy: the radionuclide,
treatment site, dose per fraction, number of fractions, and total dose;
7.11.2.5
For permanent implant brachytherapy:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

19
(1)
Before implantation: the treatment site, the radionuclide, and the total source
strength: and
(2)
After implantation but before the patient leaves the post treatment recovery area:
the treatment site, the number of sources implanted, the total source strength
implanted, and the date; or
7.11.2.6
For all other brachytherapy, including LDR, MDR, and PDR:
(1)
Before implantation: the treatment site, radionuclide, and dose; and
(2)
After implantation but before completion of the procedure: the radionuclide;
treatment site; number of sources; total source strength and exposure time (or
the total dose); and date.
7.11.3 A written revision to an existing written directive may be made if the revision is dated and signed
by an authorized user before the administration of the dosage of unsealed radioactive material,
the brachytherapy dose, the gamma stereotactic radiosurgery dose, the teletherapy dose, or the
next fractional dose.
7.11.3.1
If, because of the patient's condition, a delay in order to provide a written revision
to an existing written directive would jeopardize the patient's health, an oral revision to an
existing written directive is acceptable. The oral revision must be documented as soon as
possible in the patient's record. A revised written directive must be signed by the
authorized user within 48 hours of the oral revision.
7.11.4 The licensee shall retain a copy of each written directive and/or written revision to an existing
written directive for 3 years.
7.12
Procedures for administrations requiring a written directive.
7.12.1 For any administration requiring a written directive, the licensee shall develop, implement, and
maintain written procedures to provide high confidence that:
7.12.1.1
The patient's or human research subject's identity is verified before each
administration; and
7.12.1.2
Each administration is in accordance with the written directive.
7.12.2 At a minimum, the procedures required by 7.12.1 must address the following items that are
applicable for the licensee's use of radioactive material:
7.12.2.1
Verifying the identity of the patient or human research subject;
7.12.2.2
Verifying that the administration is in accordance with the treatment plan, if
applicable, and the written directive;
7.12.2.3
Checking both manual and computer-generated dose calculations;
7.12.2.4
Verifying that any computer-generated dose calculations are correctly transferred
into the consoles of therapeutic medical units authorized by 7.48 or 7.62.
7.12.2.5
Determining if a medical event, as defined in 7.21, has occurred; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

20
7.12.2.6
Determining, for a permanent implant brachytherapy, within 60 calendar days
from the date the implant was performed, the total source strength administered outside
of the treatment site compared to the total source strength documented in the post-
implantation portion of the written directive, unless a written justification of patient
unavailability is documented.
7.12.3 A licensee shall retain a copy of the procedures required under 7.12.1 for the duration of the
license.
7.13
Duties of authorized user and authorized medical physicist.
7.13.1 A licensee shall assure that only authorized users for the type of radioactive material used:
7.13.1.1
Prescribe the radiopharmaceutical dosage and/or dose to be administered
through the issuance of a written directive or reference to the diagnostic clinical
procedures manual; and
7.13.1.2
Direct, as specified in 7.10 and 7.12, or in license conditions, the administration
of radioactive material for medical use to patients or human research subjects;
7.13.1.3
Prepare and administer, or supervise the preparation and administration of
radioactive material for medical use, in accordance with 7.3.1.2(1), 7.3.1.2(2) and 7.10;
7.13.2 A licensee shall assure that only authorized medical physicists perform, as applicable:
7.13.2.1
Measurements and calculations as described in 7.41;
7.13.2.2
Full calibration measurements as described in 7.54, 7.55, and 7.56;
7.13.2.3
Periodic spot checks as described in 7.58, 7.59 and 7.61; and
7.13.2.4
Radiation surveys as described in 7.57.
7.14
Suppliers for sealed sources or devices for medical use.
For medical use, a licensee may only use:
7.14.1 Sealed sources or devices manufactured, labeled, packaged, and distributed in accordance with
a license issued pursuant to Part 3 of these regulations or the equivalent regulations of an
Agreement State or NRC;
7.14.2 Sealed source or devices non-commercially transferred from a Part 7 licensee or an Agreement
State or NRC medical use licensee; or
7.14.3 Teletherapy sources manufactured and distributed in accordance with a license issued pursuant
to Part 3 of these regulations, or the equivalent regulations of an Agreement State or NRC.
Section C – General Technical Requirements
7.15
Quality Control of Diagnostic Equipment.
7.15.1 Each licensee shall establish written quality control procedures for all diagnostic equipment used
for radionuclide studies.
7.15.2 As a minimum, quality control procedures and frequencies shall be:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

21
7.15.2.1
Those recommended by equipment manufacturers; or
7.15.2.2
Procedures which have been approved by the Department.
7.15.3 The licensee shall conduct quality control of diagnostic equipment in accordance with written
procedures.
7.15.4 A licensee shall retain a record of each quality control test required by the written quality control
procedures for 3 years.
7.16
Possession, use, and calibration of instruments used to measure the activity of unsealed
radioactive material.
7.16.1 For direct measurements performed in accordance with 7.18, a licensee shall possess and use
instrumentation to measure the activity of unsealed radioactive materials prior to administration to
each patient or human research subject.
7.16.2 A licensee shall calibrate the instrumentation required in 7.16.1 in accordance with nationally
recognized standards or the manufacturer's instructions.
7.16.3 In addition to the calibration required in 7.16.2, the licensee shall at a minimum also perform tests
for constancy, linearity, and geometry dependence, as appropriate to demonstrate proper
operation of the instrument.
7.16.4 A licensee shall retain a record of each instrument calibration and test required by 7.16 for 3
years. The record shall include the:
7.16.4.1
Model and serial number of the instrument;
7.16.4.2
Date of the calibration and other tests;
7.16.4.3
Results of the calibration and other tests; and
7.16.4.4
Name of the individual who performed the calibration and other tests.
7.17
Calibration of survey instruments.
7.17.1 A licensee shall calibrate the survey instruments used to show compliance with Part 4 and Part 7
before first use, annually at intervals not to exceed 12 months, and following a repair that affects
the calibration. A licensee shall:
7.17.1.1
Calibrate all scales with readings up to 10 mSv (1000 mrem) per hour with a
radiation source;
7.17.1.2
Calibrate two separate readings on each scale or decade that will be used to
show compliance; and
7.17.1.3
Conspicuously note on the instrument the date of calibration.
7.17.2 A licensee may not use survey instruments if the difference between the indicated exposure rate
and the calculated exposure rate is more than 20 percent.
7.17.3 A licensee shall retain a record of each survey instrument calibration required by 7.17 for 3 years.
The record shall include the:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

22
7.17.3.1
Model and serial number of the instrument;
7.17.3.2
Date of the calibration;
7.17.3.3
Results of the calibration; and
7.17.3.4
Name of the individual who performed the calibration.
7.18
Determination of dosages of unsealed radioactive material for medical use.
7.18.1 A licensee shall determine and record the activity of each dosage before medical use.
7.18.1.1
For photon-emitting radioactive material, this determination shall be within 30
minutes prior to medical use.
7.18.1.2
For all other radioactive material, this determination shall be within the period
before medical use that is no greater than 10 percent of the physical half-life of the
radioactive material.
7.18.2 For a unit dosage, the determination required by 7.18.1 shall be made by:
7.18.2.1
Direct measurement of radioactivity; or
7.18.2.2
A decay correction, based on the measurement made by:
(1)
A manufacturer or preparer licensed pursuant to Part 3 of these regulations or
equivalent provisions of an Agreement State, or NRC; or
(2)
An NRC or Agreement State licensee for use in research in accordance with a
Radioactive Drug Research Committee-approved protocol or an Investigational
New Drug (IND) protocol accepted by FDA.
(3)
A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or
equivalent NRC or Agreement State requirements.
7.18.3 For other than unit dosages, the determination by 7.18.1 shall be made by:
7.18.3.1
Direct measurement of radioactivity; or
7.18.3.2
Combination of measurement of radioactivity and mathematical calculations; or
7.18.3.3
Combination of volumetric measurements and mathematical calculations, based
on the measurement made by:
(1)
A manufacturer or preparer licensed pursuant to Part 3 of these regulations or
equivalent provisions of an Agreement State, or NRC.
(2)
A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or
equivalent NRC or Agreement State requirements.
7.18.4 Unless otherwise directed by the authorized user, a licensee shall not use a dosage if the dosage
differs from the prescribed dosage by more than 20 percent.
7.18.5 A license shall retain a record of the each dosage determination required by 7.18.1 for 3 years.
The record shall contain the:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

23
7.18.5.1
Name of the radioactive drug;
7.18.5.2
Patient's or human research subject’s name, and identification number if one has
been assigned;
7.18.5.3
Prescribed dosage;
7.18.5.4
Determined dosage; or a notation that the total activity is less than 1.1 MBq (30
µCi);
7.18.5.5
Date and time of the dosage determination; and
7.18.5.6
Name of the individual who determined the dosage.
7.19
Authorization for calibration, transmission and reference sources.
7.19.1 Any person authorized by 7.3 for medical use of radioactive material may receive, possess, and
use any of the following radioactive material for check, calibration, transmission and reference
use:
7.19.1.1
Sealed sources, not exceeding 1.11 GBq (30 mCi) each, manufactured and
distributed by a person licensed under Part 3, by NRC under 10 CFR 32.74 or equivalent
Agreement State regulations;
7.19.1.2
Sealed sources, not exceeding 1.11 GBq (30 mCi) each, redistributed by a
licensee authorized to redistribute the sealed sources manufactured and distributed by a
person licensed under Part 3, by NRC under 10 CFR 32.74 or equivalent Agreement
State regulations, providing the redistributed sealed sources are in the original packaging
and shielding and are accompanied by the manufacturer’s approved instructions;
7.19.1.3
Any radioactive material with a half-life not longer than 120 days or less in
individual amounts not to exceed 0.56 GBq (15 mCi);
7.19.1.4
Any radioactive material with a half life longer than 120 days in individual
amounts not to exceed the smaller of 7.4 MBq (200 uCi) or 1000 times the quantities in
Part 3 Schedule 3B; or
7.19.1.5
Technetium-99m in amounts as needed.
7.19.2 Radioactive material in sealed sources authorized by this provision shall not be:
7.19.2.1
Used for medical use as defined in 7.2 except in accordance with the
requirements in 7.40; or
7.19.2.1
Combined (i.e., bundled or aggregated) to create an activity greater than the
maximum activity of any single sealed source authorized under 7.19.
7.19.3 A licensee using calibration, transmission, and reference sources in accordance with the
requirements in 7.19.1 or 7.19.2 need not list these sources on a specific medical use license.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

24
7.20
Requirements for possession of sealed sources and brachytherapy sources.
7.20.1 A licensee in possession of any sealed source or brachytherapy source shall follow the radiation
safety and handling instructions supplied by the manufacturer or equivalent instructions approved
by the Department and shall maintain the instructions for the duration of source use in a legible
form convenient to users.
7.20.2 A licensee in possession of a sealed source shall:
7.20.2.1
Test the source for leakage before its first use unless the licensee has a
certificate from the supplier indicating that the sources was tested within 6 months before
transfer to the licensee; and
7.20.2.2
Test the source for leakage at intervals not to exceed 6 months or at intervals
approved by the Department, an Agreement State, or the NRC in the Sealed Source and
Device Registry.
7.20.2.3
A licensee shall retain records of leak tests required by 7.20.2 for 3 years. The
records must include the model number, and serial number if one has been assigned, of
each source tested; the identity of each source by radionuclide and its estimated activity;
the results of the test; the date of the test; and the name of the individual who performed
the test.
7.20.3 To satisfy the leak test requirements of 7.20, the licensee shall measure the sample so that the
leak test can detect the presence of 185 Bq (0.005 uCi) of radioactive material in the sample.
7.20.4 If the leak test reveals the presence of 0.005 microcurie (185 Bq) or more of removable
contamination, the licensee shall:
7.20.4.1
Immediately withdraw the sealed source from use and store, dispose or cause it
to be repaired in accordance with the requirements of these regulations; and
7.20.4.2
File a written report with the Department within 5 days of receiving the leak test
result, including the model number and serial number, if assigned, of the leaking source,
the radionuclide and its estimated activity, the date and results of the test, and the action
taken.
7.20.5 A licensee in possession of a sealed source or brachytherapy source, except for a gamma
stereotactic radiosurgery source, shall conduct a semi-annual physical inventory of all such
sources. The licensee shall retain each inventory record for 3 years. The inventory records must
contain the model number of each source, and serial number if one has been assigned, the
identity of each source by radionuclide and its estimated activity, the location of each source, and
the name of the individual who performed the inventory.
7.21
Report and notification of a medical event.
7.21.1 A licensee shall report any event as a medical event, except for an event that results from patient
or human research subject intervention, in which:
7.21.1.1
The administration of radioactive material or radiation from radioactive material,
except permanent implant brachytherapy, results in:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

25
(1)
A dose that differs from the prescribed dose or dose that would have resulted
from the prescribed dosage by more than 0.05 Sv (5 rem) effective dose
equivalent, 0.5 Sv (50 rem) to an organ or tissue, or 0.5 Sv (50 rem) shallow
dose equivalent to the skin; and
(a)
The total dose delivered differs from the prescribed dose by 20 percent
or more;
(b)
The total dosage delivered differs from the prescribed dosage by 20
percent or more or falls outside the prescribed dosage range; or
(c)
The fractionated dose delivered differs from the prescribed dose, for a
single fraction, by 50 percent or more.
(2)
A dose that exceeds 0.05 Sv (5 rem) effective dose equivalent, 0.5 Sv (50 rem)
to an organ or tissue, or 0.5 Sv (50 rem) shallow dose equivalent to the skin from
any of the following:
(a)
An administration of a wrong radioactive drug containing radioactive
material or the wrong radionuclide for a brachytherapy procedure;
(b)
An administration of a radioactive drug containing radioactive material by
the wrong route of administration;
(c)
An administration of a dose or dosage to the wrong individual or human
research subject;
(d)
An administration of a dose or dosage delivered by the wrong mode of
treatment; or
(e)
A leaking sealed source.
(3)
A dose to the skin or an organ or tissue other than the treatment site that
exceeds by:
(a)
0.5 Sievert (50 rem) or more the expected dose to that site from the
procedure if the administration had been given in accordance with the
written directive prepared or revised before administration; and
(b)
50 percent or more the expected dose to that site from the procedure if
the administration had been given in accordance with the written
directive prepared or revised before administration.
7.21.1.2
For permanent implant brachytherapy, the administration of radioactive material
or radiation from radioactive material (excluding sources that were implanted in the
correct site but migrated outside the treatment site) that results in:
(1)
The total source strength administered differing by 20 % or more from the total
source strength documented in the post-implantation portion of the written
directive;
(2)
The total source strength administered outside of the treatment site exceeding 20
% of the total source strength documented in the post-implantation portion of the
written directive; or
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

26
(3)
An administration that includes any of the following:
(a)
The wrong radionuclide;
(b)
The wrong individual or human research subject;
(c)
Sealed source(s) implanted directly into a location discontiguous from
the treatment site, as documented in the post-implantation portion of the
written directive; or
(d)
A leaking sealed source resulting in a dose that exceeds 0.5 Sv (50 rem)
to an organ or tissue.
7.21.2 A licensee shall report any event resulting from intervention of a patient or human research
subject in which the administration of radioactive material or radiation from radioactive material
results, or will result in, unintended permanent functional damage to an organ or a physiological
system, as determined by a physician.
7.21.3 The licensee shall notify by telephone the Department no later than the next calendar day after
discovery of the medical event.
7.21.4 The licensee shall submit a written report to the Department within 15 days after discovery of the
medical event.
7.21.4.1
The written report must include:
(1)
The licensee's name;
(2)
The name of the prescribing physician;
(3)
A brief description of the event;
(4)
Why the event occurred;
(5)
The effect, if any, on the individual(s) who received the administration;
(6)
What actions, if any, have been taken, or are planned to prevent recurrence; and
(7)
Certification that the licensee notified the individual (or the individual's
responsible relative or guardian), and if not, why not.
7.21.4.2
The report may not contain the individual's name or any other information that
could lead to identification of the individual.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

27
7.21.5 The licensee shall provide notification of the medical event to the referring physician and also
notify the individual who is the subject of the medical event no later than 24 hours after its
discovery, unless the referring physician personally informs the licensee either that he or she will
inform the individual or that, based on medical judgment, telling the individual would be harmful.
The licensee is not required to notify the individual without first consulting the referring physician.
If the referring physician or the affected individual cannot be reached within 24 hours, the
licensee shall notify the individual as soon as possible thereafter. The licensee may not delay any
appropriate medical care for the individual, including any necessary remedial care as a result of
the medical event, because of any delay in notification. To meet the requirements of 7.21.5, the
notification of the individual who is the subject of the medical event may be made instead to that
individual's responsible relative or guardian. If a verbal notification is made, the licensee shall
inform the individual, or appropriate responsible relative or guardian, that a written description of
the event can be obtained from the licensee upon request. The licensee shall provide such a
written description if requested.
7.21.6 Aside from the notification requirement, nothing in this section affects any rights or duties of
licensees and physicians in relation to each other, to individuals affected by the medical event, or
to that individual's responsible relatives or guardians.
7.21.7 A licensee shall:
7.21.7.1
Annotate a copy of the report provided to the Department with the:
(1)
Name of the individual who is the subject of the event; and
(2)
Identification number or if no other identification number is available, the social
security number of the individual who is the subject of the event; and
7.21.7.2
Provide a copy of the annotated report to the referring physician, if other than the
licensee, no later than 15 days after the discovery of the event.
7.22
Notification to the Department of deceased patients or human research subjects
containing radioactive material.
7.22.1 The licensee shall notify the Department by telephone immediately upon discovery that a patient
or human research subject containing radioactive material has died, and it is possible that any
individual could receive exposures in excess of Part 4, section 4.14 as a result of the deceased's
body.
7.22.2 The licensee shall submit a written report to the Department within 30 days after discovery that
the patient or human research subject referenced in 7.22.1 has died. The written report must
include the:
7.22.2.1
Licensee's name;
7.22.2.2
Date of death;
7.22.2.3
Radionuclide, chemical and physical form and calculated activity at time of death;
and
7.22.2.4
Names (or titles) and address(es) of known individuals who might have received
exposures exceeding 5 mSv (500 mrem).
7.22.3 The licensee shall retain a record of each written report required by 7.22 for 3 years.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

28
7.23
Report and notification of a dose to an embryo/fetus or a nursing child
7.23.1 A licensee shall report any dose to an embryo/fetus that is greater than 5 mSv (500 mrem) dose
equivalent that is a result of an administration of radioactive material or radiation from radioactive
material to a pregnant individual unless the dose to the embryo/fetus was specifically approved,
in advance, by the authorized user.
7.23.2 A licensee shall report any dose to a nursing child, that was not specifically approved, in advance,
by the authorized user, that is a result of an administration of radioactive material to a breast
feeding individual that:
7.23.2.1
Is greater than 5 millisievert (500 mrem) total effective dose equivalent; or
7.23.2.2
Has resulted in unintended permanent functional damage to an organ or a
physiological system of the child, as determined by a physician.
7.23.3 The licensee shall notify by telephone the Department no later than the next calendar day after
discovery of a dose to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.
7.23.4 The licensee shall submit a written report to the Department within 15 days after discovery of a
dose to the embryo/fetus or nursing child that requires a report in 7.23.1 or 7.23.2.
7.23.4.1
The written report must include:
(1)
The licensee's name;
(2)
The name of the prescribing physician;
(3)
A brief description of the event;
(4)
Why the event occurred;
(5)
The effect on the embryo/fetus or the nursing child;
(6)
What actions, if any, have been taken, or are planned, to prevent recurrence; and
(7)
Certification that the licensee notified the pregnant individual or mother (or the
mother's or child's responsible relative or guardian), and if not, why not.
7.23.4.2
The report must not contain the individual's or child's name or any other
information that could lead to identification of the individual or child.
7.23.5 The licensee shall provide notification of the event to the referring physician and also notify the
pregnant individual or mother, both hereafter referred to as the mother, no later than 24 hours
after discovery of an event that would require reporting under 7.23.1 or 7.23.2, unless the
referring physician personally informs the licensee either that he or she will inform the mother or
that, based on medical judgment, telling the mother would be harmful. The licensee is not
required to notify the mother without first consulting with the referring physician. If the referring
physician or mother cannot be reached within 24 hours, the licensee shall make the appropriate
notifications as soon as possible thereafter. The licensee may not delay any appropriate medical
care for the embryo/fetus or for the nursing child, including any necessary remedial care as a
result of the event, because of any delay in notification. To meet the requirements of 7.23.5, the
notification may be made to the mother's or child's responsible relative or guardian instead of the
mother, when appropriate. If a verbal notification is made, the licensee shall inform the mother, or
the mother's or child's responsible relative or guardian, that a written description of the event can
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

29
be obtained from the licensee upon request. The licensee shall provide such a written description
if requested.
7.23.6 A licensee shall:
7.23.6.1
Annotate a copy of the report provided to the Department with the:
(1)
Name of the pregnant individual or the nursing child who is the subject of the
event; and
(2)
Identification number or if no other identification number is available, the social
security number of the individual who is the subject of the event.
7.23.7 A copy of the record required under 7.23.6 shall be provided to the referring physician, if other
than the licensee, within 15 days after discovery of the event.
7.24
Labeling of vials and syringes.
7.24.1 A licensee shall require each individual preparing or handling a vial that contains a
radiopharmaceutical to keep the vial in a vial radiation shield.
7.24.2 Each syringe and vial that contains a radioactive drug shall be labeled to identify the radioactive
drug, to include the isotope and amount of radioactivity. Each syringe shield and vial shield shall
also be labeled unless the label on the syringe or vial is visible when shielded.
7.25
Surveys for contamination and ambient exposure rate.
7.25.1 Surveys required by 7.25.2 and 7.25.3 are in addition to surveys required by Part 4.
7.25.2 Daily Survey Requirements
7.25.2.1
At the end of each day of use, a licensee shall survey with an exposure rate
instrument, all areas where radioactive drugs containing radioactive material requiring a
written directive were prepared for use or administered.
(1)
A licensee does not need to perform the surveys required by 7.25.2.1 in an area
where patients or human research subjects are confined when they cannot be
released pursuant to 7.26.
7.25.2.2
At the end of each day of use, a licensee shall survey for removable
contamination all areas where generators and bulk radioactive drugs are prepared for
use. An instrument capable of detecting 33.3 becquerels (2000 dpm) of contamination on
each wipe sample shall be used.
7.25.3 Weekly Survey Requirements
7.25.3.1
At least once each week, a licensee shall survey, with an exposure rate
instrument, all areas where radioactive drugs or radioactive wastes are stored.
7.25.3.2
At least once each week, a licensee shall survey for removable contamination in
all areas where radioactive materials other than sealed sources as defined in Part 7 are
stored. An instrument capable of detecting 33.3 becquerels (2000 dpm) of contamination
on each wipe sample shall be used.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

30
7.25.4 A licensee shall establish action levels for the surveys required by 7.25.2 and 7.25.3 and shall
require that the individual performing the survey immediately notify the Radiation Safety Officer if
action levels are exceeded.
7.25.5 A licensee shall retain a record of each survey required by 7.25.1, 7.25.2 and 7.25.3 for 3 years.
The record must include:
7.25.5.1
The date of the survey;
7.25.5.2
The results of the survey;
7.25.5.3
The instrument used to make the survey (including, if applicable, that the
instrument was checked for consistent response with a dedicated check source prior to
each daily use); and
7.25.5.4
The name of the individual who performed the survey.
7.26
Release of individuals containing unsealed radioactive material or implants containing
radioactive material.
7.26.1 A licensee may authorize the release from the licensee’s control of any individual who has been
administered radioactive drugs or permanent implants containing radioactive material if the total
effective dose equivalent to any other individual from exposure to the released individual is not
likely to exceed 5 mSv (0.5 rem).1
1 Appendix U of U.S. Nuclear Regulatory Commission NUREG-1556, Vol. 9, “Consolidated Guidance About Materials Licenses:
Program Specific Guidance About Medical Licenses” describes methods for calculating doses to other individuals and contains
tables of activities not likely to cause doses exceeding 5 mSv (0.5 rem).
7.26.2 A licensee shall provide the released individual or the individual’s parent or guardian with
instructions, including written instructions on the actions recommended to maintain doses to other
individuals as low as is reasonably achievable if the total effective dose equivalent to any other
individual is likely to exceed 1 mSv (0.1 rem).
7.26.2.1
If the total effective dose equivalent to a nursing infant or child could exceed 1
mSv (0.1 rem) assuming there were no interruption in breast-feeding, the instructions
shall also include:
(1)
Guidance on the interruption or discontinuation of breast-feeding; and
(2)
Information on the potential consequences, if any, of failure to follow the
guidance.
7.26.3 If the total effective dose equivalent to a nursing infant or child could exceed 5 mSv (0.5 rem)
from continued breast-feeding, the licensee shall maintain a record that the instructions required
by 7.26.2 were provided to a breast-feeding woman.
7.26.4 The licensee shall maintain a record of the basis for authorizing the release of an individual in
accordance with 7.26, if the total effective dose equivalent is calculated by:
7.26.4.1
Using the retained activity rather than the administered activity;
7.26.4.2
Using an occupancy factor less than 0.25 at 1 meter;
7.26.4.3
Using the biological or effective half-live; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

31
7.26.4.4
Considering the shielding by tissue.
7.26.5 The records required by 7.26.3 and 7.26.4 must be retained for 3 years after the date of release
of the individual.
7.26.6 Reports of Patient Departure Prior to Authorized Release.
7.26.6.1
The licensee shall notify the Department by telephone immediately upon
discovery that a patient or human research subject has departed from the licensee's
facility without authorization under 7.26.
7.26.6.2
The licensee shall submit a written report to the Department within 30 days after
discovery of the unauthorized departure. The written report must include:
(1)
The licensee's name;
(2)
The date and time of the unauthorized departure;
(3)
The projected date and time when release would have occurred;
(4)
The address of the patient's or human research subject's home or anticipated
destination following departure;
(5)
The radionuclide, chemical and physical form and calculated activity at time of
release;
(6)
The apparent reason(s) for the departure prior to authorized release; and
(7)
A description of any changes in the licensee's patient release criteria or patient
instructions that are designed to avoid a recurrence of such an event.
7.27
Mobile nuclear medicine service technical requirements.
A licensee providing mobile nuclear medicine service shall:
7.27.1 Transport to each client’s address of use only syringes or vials containing prepared drugs or
radioactive materials that are intended for reconstitution of radioactive drug kits;
7.27.2 Bring into each client’s address of use all radioactive material to be used and, before leaving,
remove all unused radioactive material and associated radioactive waste;
7.27.3 Secure or keep under constant surveillance and immediate control all radioactive material when
in transit or at a client’s address of use;
7.27.4 Check instruments used to measure the activity of unsealed radioactive material for proper
function before medical use at each client's address or on each day of use, whichever is more
frequent. At a minimum, the check for proper function shall include a constancy check;
7.27.5 Check survey instruments for consistent response with a dedicated check source before use at
each client's address;
7.27.6 Prior to leaving a client’s address of use, perform area surveys and survey for removable
contamination in all areas of use, to ensure compliance with Part 4 of these regulations; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

32
7.27.7 Retain a record of each survey required by 7.27.6 for 3 years. The record must include the date
of the survey, the results of the survey, the instrument used to make the survey, and the name of
the individual who performed the survey.
7.28
Storage of Volatiles and Gases.
7.28.1 A licensee shall store volatile radioactive materials and radioactive gases in a radiation shield and
container.
7.28.2 A licensee shall store and use a multi-dose container in a properly functioning fume hood.
7.28.3 A licensee who administers radioactive aerosols or gases shall do so with a system that will keep
airborne concentrations within the limits prescribed in Part 4 of these regulations.
7.28.3.1
The system shall either be directly vented to the atmosphere through an air
exhaust or provide for collection and decay or disposal of the aerosol or gas in a shielded
container.
7.28.3.2
A licensee shall check the operation of collection systems monthly. Records of
these checks shall be maintained for 3 years.
7.29
Decay-in-storage.
7.29.1 A licensee may hold radioactive material with a physical half-life of less than or equal to 120 days
for decay-in-storage before disposal without regard to its radioactivity if it:
7.29.1.1
Monitors radioactive material at the surface before disposal and determines that
its radioactivity cannot be distinguished from the background radiation level with an
appropriate radiation detection survey meter set on its most sensitive scale and with no
interposed shielding; and
7.29.1.2
Removes or obliterates all radiation labels, except for radiation labels on
materials that are within containers and that will be managed as biomedical waste after
they have been released from the licensee; and
7.29.2 Records of Decay-in-Storage.
A licensee shall retain a record of each disposal permitted under 7.29.1 as follows:
7.29.2.1
A licensee shall maintain records of the disposal of licensed materials, as
required by 7.29, for 3 years. The record must include the date of the disposal, the survey
instrument used, the background radiation level, the radiation level measured at the
surface of each waste container, and the name of the individual who performed the
survey.
Section D – Unsealed Radioactive Material – Written Directive Not Required
7.30
Use of unsealed radioactive material for uptake, dilution, and excretion studies for which a
written directive is not required.
7.30.1 Except for quantities that require a written directive under 7.11.2, a licensee may use any
unsealed radioactive material prepared for medical use for uptake, dilution, or excretion studies
that is:
7.30.1.1
Obtained from:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

33
(1)
A manufacturer or preparer licensed under Part 3, Section 3.12.10 or equivalent
regulations of an Agreement State, or NRC; or;
(2)
A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or
equivalent regulations of an Agreement State or NRC; or
7.30.1.2
Excluding production of PET radionuclides, prepared by:
(1)
An authorized nuclear pharmacist;
(2)
A physician who is an authorized user and who meets the requirements specified
in Appendix 7E, or Appendix 7F and Section 7E3.1(2)(g) of Appendix 7E; or
(3)
An individual under the supervision, as specified in 7.10, of the authorized
nuclear pharmacist in 7.30.1.2(1) or the physician who is an authorized user in
7.30.1.2(2); or
7.30.1.3
Obtained from and prepared by a Department, Agreement State, or NRC
licensee for use in research in accordance with a Radioactive Drug Research Committee-
approved protocol or an Investigational New Drug (IND) protocol accepted by FDA; or
7.30.1.4
Prepared by the licensee for use in research in accordance with a Radioactive
Drug Research Committee-approved application or an Investigational New Drug (IND)
protocol accepted by FDA.
7.30.2 Training For Uptake, Dilution, And Excretion Studies.
The licensee shall require an authorized user of unsealed radioactive material for the uses
authorized under 7.30 to meet the requirements of Appendix 7D.
7.31
Reserved
7.32
Use of unsealed radioactive material for imaging and localizations studies for which a
written directive is not required.
Except for quantities that require a written directive under 7.11, a licensee may use any unsealed
radioactive material prepared for medical use for imaging and localization studies that is:
7.32.1 Obtained from:
7.32.1.1
A manufacturer or preparer licensed pursuant to Part 3, Section 3.12.10 or
equivalent regulations of an Agreement State, or NRC; or
7.32.1.2
A PET radioactive drug producer licensed under Part 3, Section 3.8.10; or
7.32.2 Excluding production of PET radionuclides, prepared by:
7.32.2.1
An authorized nuclear pharmacist;
7.32.2.2
A physician who is an authorized user and who meets the requirements specified
in Appendix 7E, or Appendix 7F and 7E3.1(2)(g); or
7.32.2.3
An individual under the supervision, as specified in 7.10, of the authorized
nuclear pharmacist in 7.32.2.1 or the physician who is an authorized user in 7.32.2.2;
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

34
7.32.3 Obtained from and prepared by a Department, Agreement State, or NRC licensee for use in
research in accordance with a Radioactive Drug Research Committee-approved protocol or an
Investigational New Drug (IND) protocol accepted by FDA; or
7.32.4 Prepared by the licensee in accordance with a Radioactive Drug Research Committee-approved
application or an Investigational New Drug (IND) protocol accepted by FDA for use in research.
7.32.5 Authorized User Training for Imaging and Localization Studies for which a Written Directive is Not
Required.
The licensee shall require an authorized user of an unsealed radioactive material for the uses
authorized under 7.32 to meet the requirements of Appendix 7E.
7.33
Permissible molybdenum-99, strontium-82, and strontium-85 concentrations.
7.33.1 A licensee may not administer to humans a radioactive drug that contains:
7.33.1.1
More than 0.15 kBq of molybdenum-99 per MBq of technetium-99m (0.15 µCi of
99Mo per mCi of 99mTc); or
7.33.1.2
More than 0.02 kBq of strontium-82 per MBq of rubidium-82 chloride injection
(0.02 µCi of 82Sr per mCi of 82Rb chloride); or more than 0.2 kBq of strontium-85 per
MBq of rubidium-82 chloride injection (0.2 µCi of 85Sr per mCi of 82Rb).
7.33.2 A licensee that uses molybdenum-99/technetium-99m generators for preparing a technetium-99m
radioactive drug shall measure the molybdenum-99 concentration in each eluate from a generator
to demonstrate compliance with 7.33.1.
7.33.3 A licensee that uses a strontium-82/rubidium-82 generator for preparing a rubidium-82 radioactive
drug shall, before the first patient use of the day, measure the concentration of radionuclides
strontium-82 and strontium-85 to demonstrate compliance with 7.33.1.
7.33.4 If a licensee is required to measure the molybdenum-99 concentration or strontium-82 and
strontium-85 concentrations, the licensee shall retain a record of each measurement as follows:
7.33.4.1
A licensee shall maintain a record of the molybdenum-99 concentration or
strontium-82 and strontium-85 concentration tests required by 7.33.2 and 7.33.3 for 3
years. The record must include:
(1)
For each measured elution of technetium-99m, the ratio of the measures
expressed as kilobecquerel of molybdenum-99 per megabecquerel of
technetium-99m (or microcuries of molybdenum per millicurie of technetium), the
time and date of the measurement, and the name of the individual who made the
measurement; or
(2)
For each measured elution of rubidium-82, the ratio of the measures expressed
as kilobecquerel of strontium-82 per megabecquerel of rubidium-82 (or
microcuries of strontium-82 per millicurie of rubidium), kilobecquerel of strontium-
85 per megabecquerel of rubidium-82 (or microcuries of strontium-85 per
millicurie of rubidium), the time and date of the measurement, and the name of
the individual who made the measurement.
7.33.5 The licensee shall report any measurement that exceeds the limits in 7.33.1 at the time of
generator elution, as follows:
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

35
Report and notification for an eluate exceeding permissible molybdenum-99, strontium-82, and
strontium-85 concentrations.
7.33.5.1
The licensee shall notify by telephone the Department and the distributor of the
generator within 7 calendar days after discovery that an eluate exceeded the permissible
concentration listed in 7.33.1 at the time of generator elution. The telephone report to the
Department must include the manufacturer, model number, and serial number (or lot
number) of the generator; the results of the measurement; the date of the measurement;
whether dosages were administered to patients or human research subjects, when the
distributor was notified, and the action taken.
7.33.5.2
The licensee shall submit a written report to the Department within 30 calendar
days after discovery of an eluate exceeding the permissible concentration at the time of
generator elution. The written report must include the action taken by the licensee; the
patient dose assessment; the methodology used to make this dose assessment if the
eluate was administered to patients or human research subjects; and the probable cause
and an assessment of failure in the licensee’s equipment, procedures or training that
contributed to the excessive readings if an error occurred in the licensee’s breakthrough
determination; and the information in the telephone report as required by 7.33.5.1.
7.34
Aerosols and gases.
Provided the conditions of 7.28 are met, a licensee shall use radioactive aerosols or gases only if
specific application is made to and approved by the Department.
7.35
Reserved
Section E – Unsealed Radioactive Material – Written Directive Required
7.36
Use of unsealed radioactive material for which a written directive is required.
7.36.1 A licensee may use any unsealed radioactive material identified in 7F2.1(2)(f) prepared for
medical use and for which a written directive is required that is:
7.36.1.1
Obtained from:
(1)
A manufacturer or preparer licensed under Part 3, Section 3.12.10 or equivalent
regulations of NRC or an Agreement State; or
(2)
A PET radioactive drug producer licensed under Part 3, Section 3.8.10 or
equivalent Agreement State or NRC regulations; or
7.36.1.2
Excluding production of PET radioactive material, prepared by:
(1)
An authorized nuclear pharmacist;
(2)
A physician who is an authorized user and who meets the requirements specified
in Appendix 7E, or Appendix 7F; or
(3)
An individual under the supervision, as specified in 7.10, of the authorized
nuclear pharmacist in 7.36.1.2(1) or the physician who is authorized under
7.36.1.2(2); or
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

36
7.36.1.3
Obtained from and prepared by a Department, Agreement State, or NRC
licensee for use in research in accordance with an Investigational New Drug (IND)
protocol accepted by FDA; or
7.36.1.4
Prepared by the licensee for use in research in accordance with an
Investigational New Drug (IND) protocol accepted by FDA.
7.36.2 Training For Use Of Any Unsealed Radioactive Material For Diagnostic Or Therapeutic Medical
Use For Which A Written Directive Is Required.
The licensee shall require an authorized user of an unsealed radioactive material for diagnostic or
therapeutic medical use for which a written directive is required under 7.36 to meet the
requirements of Appendix 7F.
7.36.3 Training For Oral Administration of < / = 1.22 GBq 131I (33 mCi) Sodium Iodide Requiring A
Written Directive.
The licensee shall require an authorized user of an unsealed radioactive material for oral
administration of < / = 1.22 GBq 131I (33 mCi) sodium iodide requiring a written directive under
7.36 to meet the requirements of Appendix 7G.
7.36.4 Training For Oral Administration Of > 1.22 GBq 131I (33 mCi) Sodium Iodide Requiring A Written
Directive.
The licensee shall require an authorized user of an unsealed radioactive material for oral
administration of > 1.22 GBq 131I (33 mCi) sodium iodide requiring a written directive under 7.36
to meet the requirements of Appendix 7H.
7.36.5 Training For Parenteral Administration Requiring A Written Directive.
The licensee shall require an authorized user of an unsealed radioactive material for parenteral
administration requiring a written directive under 7.36 to meet the requirements of Appendix 7I.
7.37
Safety instruction.
In addition to the requirements of Part 10 of these regulations:
7.37.1 A licensee shall provide radiation safety instruction, initially and at least annually, to personnel
caring for patients or human research subjects who cannot be released in accordance with 7.26.
To satisfy this requirement, the instruction must be commensurate with the duties of the
personnel and include:
7.37.1.1
Patient or human research subject control;
7.37.1.2
Visitor control, including:
(1)
Routine visitation to hospitalized individuals in accordance with Part 4, Section
4.14.1.1 of these regulations; and
(2)
Visitation authorized in accordance with Part 4, Section 4.14.2;
7.37.1.3
Contamination control;
7.37.1.4
Waste control; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

37
7.37.1.5
Notification of the RSO, or his or her designee, and an authorized user if the
patient or the human research subject has a medical emergency or dies.
7.37.2 A licensee shall retain a record of individuals receiving safety instructions required by 7.37 and
maintain such records for 3 years. The record must include a list of the topics covered, the date of
the instruction, the name(s) of the attendee(s), and the name(s) of the individual(s) who provided
the instruction.
7.38
Safety precautions.
7.38.1 For each patient or human research subject who cannot be released under 7.26, a licensee shall:
7.38.1.1
Quarter the patient or the human research subject either in:
(1)
A private room with a private sanitary facility; or
(2)
A room, with a private sanitary facility, with another individual who also has
received therapy with unsealed radioactive material and who also cannot be
released in accordance with 7.26; and
7.38.1.2
Visibly post the patient's or the human research subject’s room with a
“Radioactive Materials” sign.
7.38.1.3
Note on the door or in the patient's or the human research subject’s chart where
and how long visitors may stay in the patient's or the human research subject’s room;
and
7.38.1.4
Either monitor material and items removed from the patient's or the human
research subject’s room to determine that their radioactivity cannot be distinguished from
the natural background radiation level with a radiation detection survey instrument set on
its most sensitive scale and with no interposed shielding, or handle the materials and
items as radioactive waste.
7.38.2 A licensee shall notify the RSO, or his or her designee, and an authorized user as soon as
possible if the patient or human research subject has a medical emergency or dies.
7.39
Reserved.
Section F – Sealed Sources for Diagnosis
7.40
Use of sealed sources and medical devices for diagnosis.
7.40.1 A licensee must use only sealed sources that are not in medical devices for diagnostic medical
uses if the sealed sources are approved in the Sealed Source and Device Registry for diagnostic
medicine. The sealed sources may be used for diagnostic medical uses that are not explicitly
listed in the Sealed Source and Device Registry but must be used in accordance with the
radiation safety conditions and limitations described in the Sealed Source and Device Registry.
7.40.2 A licensee must only use medical devices containing sealed sources for diagnostic medical uses
if both the sealed sources and medical devices are approved in the Sealed Source and Device
Registry for diagnostic medical uses. The diagnostic medical devices may be used for diagnostic
medical uses that are not explicitly listed in the Sealed Source and Device Registry but must be
used in accordance with the radiation safety conditions and limitations described in the Sealed
Source and Device Registry.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

38
7.40.3 Sealed sources and devices for diagnostic medical uses may be used in research in accordance
with an active Investigational Device Exemption (IDE) application accepted by the U.S. Food and
Drug Administration provided the requirements of 7.14.1 are met.
7.40.4 Training for use of sealed sources and medical devices for diagnosis.
The licensee shall require an authorized user under 7.40 to meet the requirements of Appendix
7J.
Section G – Manual Brachytherapy
7.41
Calibration measurements of brachytherapy sources.
7.41.1 Before the first medical use of a brachytherapy source, a licensee shall have:
7.41.1.1
Determined the source output or activity using a dosimetry system that meets the
requirements of 7.53;
7.41.1.2
Determined source positioning accuracy within applicators; and
7.41.1.3
Used published protocols currently accepted by nationally recognized bodies to
meet the requirements of 7.41.1.1 and 7.41.1.2.
7.41.2 Instead of a licensee making its own measurements as required in 7.41.1, the licensee may use
measurements provided by the source manufacturer or by a calibration laboratory accredited by
the American Association of Physicists in Medicine that are made in accordance with 7.41.1.
7.41.3 A licensee shall mathematically correct the outputs or activities determined in 7.41.1 for physical
decay at intervals consistent with 1 percent physical decay.
7.41.4 An authorized medical physicist shall perform or review the measurements and calculations made
pursuant to 7.41.1, 7.41.2, or 7.41.3.
7.41.5 A licensee shall retain a record of each calibration as follows:
7.41.5.1
A licensee shall maintain a record of the calibrations of brachytherapy sources
required by 7.41.1 for 3 years after the last use of the source.
7.41.5.2
The record must include:
(1)
The date of the calibration;
(2)
The manufacturer's name, model number, and serial number for the source and
the instruments used to calibrate the source;
(3)
The source output or activity;
(4)
The source positioning accuracy within the applicators; and
(5)
The name of the individual, the source manufacturer, or the calibration laboratory
that performed the calibration.
7.41.6 Strontium-90 sources for ophthalmic treatments.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

39
7.41.6.1
Licensees who use strontium-90 for ophthalmic treatments must ensure that
certain activities as specified in 7.41.6.2 are performed by either:
(1)
An authorized medical physicist; or
(2)
An individual who:
(a)
Is identified as an ophthalmic physicist on a specific medical use license
issued by NRC or an Agreement State; permit issued by a NRC or
Agreement State broad scope medical use licensee; medical use permit
issued by a NRC master material licensee; or permit issued by a NRC
master material license broad scope medical use permittee; and
(b)
Holds a master’s or doctor’s degree in physics, medical physics, other
physical sciences, engineering, or applied mathematics from an
accredited college or university; and
(c)
Has successfully completed 1 year full-time training in medical physics
and an additional year of full-time work experience under the supervision
of a medical physicist; and
(d)
Has documented training in:
(i)
The creation, modification, and completion of written directives;
(ii)
Procedures for administrations requiring a written directive; and
(iii)
Performing the calibration measurements of brachytherapy
sources as detailed in 7.41.1 through 7.41.5.
7.41.6.2
The individuals who are identified in 7.41.6.1 must:
(1)
Calculate the activity of each strontium-90 source that is used to determine the
treatment times for ophthalmic treatments. The decay must be based on the
activity determined under 7.41.1 through 7.41.5; and
(2)
Assist the licensee in developing, implementing, and maintaining written
procedures to provide high confidence that the administration is in accordance
with the written directive. These procedures must include the frequencies that the
individual meeting the requirements in 7.41.6.1 will observe treatments, review
the treatment methodology, calculate treatment time for the prescribed dose, and
review records to verify that the administrations were in accordance with the
written directives.
7.41.6.3
Licensees must retain a record of the activity of each strontium-90 source as
follows:
(1)
A licensee shall maintain a record of the activity of a strontium-90 source
required by 7.41.6 for the life of the source.
(2)
The record must include:
(a)
The date and initial activity of the source as determined under 7.41.1
through 7.41.5; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

40
(b)
For each decay calculation, the date and the source activity as
determined under 7.41.6.
7.42
Use of sealed sources for manual brachytherapy.
7.42.1 A licensee must use only brachytherapy sources:
7.42.1.1
Approved in the Sealed Source and Device Registry for manual brachytherapy
use. The manual brachytherapy sources may be used for manual brachytherapy uses
that are not explicitly listed in the Sealed Source and Device Registry, but must be used
in accordance with the radiation safety conditions and limitations described in the Sealed
Source and Device Registry; or
7.42.1.2
In research to deliver therapeutic doses for medical use in accordance with an
active Investigational Device Exemption (IDE) application accepted by the FDA provided
the requirements of 7.14.1 are met.
7.42.2 Authorized User Training For Use Of Sealed Sources For Manual Brachytherapy.
The licensee shall require an authorized user under 7.42 to meet the requirements of Appendix
7K.
7.42.3 Authorized User Training For Use Of Strontium-90 Sealed Sources For Ophthalmic Uses.
The licensee shall require an authorized user of strontium-90 sealed sources for ophthalmic uses
under 7.42 to meet the requirements of Appendix 7L.
7.43
Safety instruction.
In addition to the requirements of Part 10 of these regulations:
7.43.1 The licensee shall provide radiation safety instruction, initially and at least annually, to personnel
caring for patients or human research subjects that are undergoing implant therapy and cannot
be released in accordance with 7.26.
7.43.2 The instruction required by 7.43.1 shall be commensurate with the duties of the personnel and
include:
7.43.2.1
Size and appearance of the brachytherapy sources;
7.43.2.2
Safe handling and shielding instructions in case of a dislodged source;
7.43.2.3
Patient or human research subject control;
7.43.2.4
Visitor control, including both;
(1)
Routine visitation to hospitalized individuals in accordance with Part 4, Section
4.14.1.1; and
(2)
Visitation authorized in accordance with Part 4, Section 4.14.3; and
7.43.2.5
Notification of the RSO, or his or her designee, and the authorized user if the
patient or the human research subject dies or has a medical emergency.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

41
7.43.3 A licensee shall retain a record of individuals receiving safety instructions required by 7.43.1 and
maintain such records for 3 years. The record must include a list of the topics covered, the date of
the instruction, the names(s) of the attendee(s), and the name(s) of the individual(s) who provided
the instruction.
7.44
Safety precautions.
7.44.1 For each patient or the human research subject that is receiving brachytherapy and cannot be
released in accordance with 7.26, a licensee shall:
7.44.1.1
Not place the patient or the human research subject in the same room with a
patient who is not receiving radiation therapy;
7.44.1.2
Visibly post the patient's or human research subject’s door with a “Caution:
Radioactive Material” sign and note on the door or on the patient's or human research
subject’s chart where and how long visitors may stay in the patient's or human research
subject’s room.
7.44.2 A licensee shall have emergency response equipment available near each treatment room to
respond to a source that inadvertently becomes:
7.44.2.1
Dislodged from the patient; or
7.44.2.2
Lodged within the patient following removal of the source applicators.
7.44.3 A licensee shall notify the RSO, or his or her designee, and an authorized user as soon as
possible if the patient or human research subject has a medical emergency or dies.
7.45
Brachytherapy sources inventory.
7.45.1 A licensee shall maintain accountability at all times for all brachytherapy sources in storage or
use.
7.45.2 As soon as possible after removing brachytherapy sources from a patient or a human research
subject, a licensee shall return brachytherapy sources to a secure storage area and count or
otherwise verify the number returned to ensure that all sources taken from the storage area have
been returned.
7.45.3 A licensee shall maintain a record of brachytherapy source accountability for 3 years.
7.45.3.1
For temporary implants, the record must include:
(1)
The number and activity of sources removed from storage, the time and date
they were removed from storage, the name of the individual who removed them
from storage, and the location of use; and
(2)
The number and activity of sources returned to storage, the time and date they
were returned to storage, and the name of the individual who returned them to
storage.
7.45.3.2
For permanent implants, the record must include:
(1)
The number and activity of sources removed from storage, the date they were
removed from storage, and the name of the individual who removed them from
storage;
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

42
(2)
The number and activity of sources not implanted, the date they were returned to
storage, the date they were returned to storage, and the name of the individual
who returned them to storage; and
(3)
The number and activity of sources permanently implanted in the patient or
human research subject.
7.46
Surveys after source implant and removal.
7.46.1 Immediately after implanting sources in a patient or a human research subject, the licensee shall
perform a survey to locate and account for all sources that have not been implanted.
7.46.2 Immediately after removing the last temporary implant source from a patient or a human research
subject, the licensee shall perform a radiation survey of the patient with a radiation detection
survey instrument to confirm that all sources have been removed. The licensee shall not release
from confinement for medical care a patient treated by temporary implant until all sources have
been removed.
7.46.3 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.46.1
and 7.46.2 for 3 years. Each record must include the date and results of the survey, the survey
instrument used, and the name of the individual who made the survey.
7.47
Therapy-related computer systems.
7.47.1 The licensee shall perform acceptance testing on the treatment planning system of therapy-
related computer systems in accordance with published protocols accepted by nationally
recognized bodies.
7.47.2 At a minimum, the acceptance testing required by 7.47.1 shall include, as applicable, verification
of:
7.47.2.1
The source-specific input parameters required by the dose calculation algorithm;
7.47.2.2
The accuracy of dose, dwell time, and treatment time calculations at
representative points;
7.47.2.3
The accuracy of isodose plots and graphic displays; and
7.47.2.4
The accuracy of the software used to determine radioactive source positions
from radiographic images.
Section H - Photon Emitting Remote Afterloader Units, Teletheraphy Units, and Gamma
Stereotactic Radiosurgery Units
7.48
Use of a sealed source in a remote afterloader unit, teletherapy unit, or gamma
stereotactic radiosurgery unit.
7.48.1 A licensee must only use sealed sources:
7.48.1.1
Approved and as provided for in the Sealed Source and Device Registry in
photon emitting remote afterloader units, teletherapy units, or gamma stereotactic
radiosurgery units to deliver therapeutic doses for medical uses; or
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

43
7.48.1.2
In research involving photon-emitting remote afterloader units, teletherapy units,
or gamma stereotactic radiosurgery units in accordance with an active Investigational
Device Exemption (IDE) application accepted by the U.S. Food and Drug Administration
provided the requirements of 7.14.1 are met.
7.48.2 A licensee must use photon-emitting remote afterloader units, teletherapy units, or gamma
stereotactic radiosurgery units:
7.48.2.1
Approved in the Sealed Source and Device Registry to deliver a therapeutic dose
for medical use. These devices may be used for therapeutic medical treatments that are
not explicitly provided for in the Sealed Source and Device Registry, but must be used in
accordance with radiation safety conditions and limitations described in the Sealed
Source and Device Registry; or
7.48.2.2
In research in accordance with an active Investigational Device Exemption (IDE)
application accepted by the FDA provided the requirements of 7.14.1 are met.
7.48.3 Training For Use of a Remote Afterloader Unit, Teletherapy Unit, or Gamma Stereotactic
Radiosurgery Unit.
The licensee shall require an authorized user under 7.48 to meet the requirements of Appendix
7M.
7.49
Installation, maintenance, adjustment, and repair.
7.49.1 Only a person specifically licensed by the Department, an Agreement State, or the NRC shall
install, maintain, adjust, or repair a remote afterloader unit, teletherapy unit, or gamma
stereotactic radiosurgery unit that involves work on the source(s) shielding, the source(s) driving
unit, or other electronic or mechanical component that could expose the source(s), reduce the
shielding around the source(s), or compromise the radiation safety of the unit or the source(s).
7.49.2 Except for low dose-rate remote afterloader units, only a person specifically licensed by the
Department, an Agreement State, or the NRC shall install, replace, relocate, or remove a sealed
source or source contained in other remote afterloader units, teletherapy units, or gamma
stereotactic radiosurgery units.
7.49.3 For a low dose-rate remote afterloader unit, only a person specifically licensed by the
Department, an Agreement State, or the NRC, or an authorized medical physicist shall install,
replace, relocate, or remove a sealed source(s) contained in the unit.
7.49.4 A licensee shall retain a record of the installation, maintenance, adjustment and repair of remote
afterloader units, teletherapy units, and gamma stereotactic radiosurgery units for 3 years. For
each installation, maintenance, adjustment and repair, the record must include the date,
description of the service, and name(s) of the individual(s) who performed the work.
7.50
Surveys of patients and human research subjects treated with a remote afterloader.
7.50.1 Before releasing a patient or a human research subject from licensee control, a licensee shall
make a survey of the patient or the human research subject and the remote afterloader unit with a
portable radiation detection survey instrument to confirm that the source(s) has been removed
from the patient or human research subject and returned to the safe shielded position.
7.50.2 A licensee shall maintain a record of patient surveys which demonstrate compliance with 7.50.1
for 3 years. Each record shall include the date and results of the survey, the survey instrument
used, and the name of the individual who made the survey.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

44
7.51
Safety procedures and instructions for remote afterloader units, teletherapy units, or
gamma stereotactic radiosurgery units.
7.51.1 A licensee shall:
7.51.1.1
Secure the unit, the console, the console keys, and the treatment room when not
in use or unattended;
7.51.1.2
Permit only individuals approved by the authorized user, RSO, or authorized
medical physicist to be present in the treatment room during treatment with the source(s);
7.51.1.3
Prevent dual operation of more than one radiation producing device in a
treatment room, if applicable; and
7.51.1.4
Develop, implement, and maintain written procedures for responding to an
abnormal situation when the operator is unable to place the source(s) in the shielded
position, or remove the patient or human research subject from the radiation field with
controls from outside the treatment room. These procedures must include:
(1)
Instructions for responding to equipment failures and the names of the individuals
responsible for implementing corrective actions;
(2)
The process for restricting access to and posting of the treatment area to
minimize the risk of inadvertent exposure; and
(3)
The names and telephone numbers of the authorized users, the authorized
medical physicist, and the RSO to be contacted if the unit or console operates
abnormally.
7.51.2 A copy of the procedures required by 7.51.1.4 must be physically located at the unit console.
7.51.3 A licensee shall post instructions at the unit console to inform the operator of:
7.51.3.1
The location of the procedures required by 7.51.1.4; and
7.51.3.2
The names and telephone numbers of the authorized users, the authorized
medical physicist, and the Radiation Safety Officer to be contacted if the unit or console
operates abnormally.
7.51.4 Operational and safety training.
7.51.4.1
Prior to the first use for patient treatment of a new unit or an existing unit with a
manufacturer upgrade that affects the operation and safety of the unit, a licensee shall
ensure that vendor operational and safety training is provided to all individuals who will
operate the unit. The vendor operational and safety training must be provided by the
device manufacturer or by an individual certified by the device manufacturer to provide
the operational and safety training.
7.51.4.2
A licensee shall provide operational and safety instructions, initially and at least
annually, to all individuals who operate the unit at the facility, as appropriate to the
individual's assigned duties. The instructions shall include instruction in:
(1)
The procedures identified in 7.51.1.4; and
(2)
The operating procedures for the unit.
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

45
7.51.5 A licensee shall ensure that operators, authorized medical physicists, and authorized users
participate in drills of the emergency procedures, initially and at least annually.
7.51.6 A licensee shall retain a record of individuals receiving instruction required by 7.51.4 in
accordance with the following:
(1)
A licensee shall maintain a record of the operational and safety instructions
required by 7.51.4 for 3 years. The record must include a list of the topics
covered, the date of the instruction, the name(s) of the attendee(s), and the
name(s) of the individual(s) who provided the instruction.
7.51.7 A licensee shall retain a copy of the procedures required by 7.51.1.4 and 7.51.4.2(2) until the
licensee no longer possesses the remote afterloader, teletherapy unit, or gamma stereotactic
radiosurgery unit.
7.52
Safety precautions for remote afterloader units, teletherapy units, and gamma stereotactic
radiosurgery units.
7.52.1 A licensee shall control access to the treatment room by a door at each entrance.
7.52.2 A licensee shall equip each entrance to the treatment room with an electrical interlock system that
will:
7.52.2.1
Prevent the operator from initiating the treatment cycle unless each treatment
room entrance door is closed;
7.52.2.2
Cause the source(s) to be shielded when an entrance door is opened; and
7.52.2.3
Prevent the source(s) from being exposed following an interlock interruption until
all treatment room entrance doors are closed and the source(s)’ on/off control is reset at
the console.
7.52.3 A licensee shall require any individual entering the treatment room to assure, through the use of
appropriate radiation monitors, that radiation levels have returned to ambient levels.
7.52.4 Except for low-dose remote afterloader units, a licensee shall construct or equip each treatment
room with viewing and intercom systems to permit continuous observation of the patient or the
human research subject from the treatment console during irradiation.
7.52.5 For licensed activities where sources are placed within the patient's or human research subject's
body, a licensee shall only conduct treatments which allow for expeditious removal of a
decoupled or jammed source.
7.52.6 In addition to the requirements specified in 7.52.1 through 7.52.5, a licensee shall:
7.52.6.1
For low dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader
units, require:
(1)
An authorized medical physicist and either an authorized user or a physician,
under the supervision of an authorized user, who has been trained in the
operation and emergency response for the unit, to be physically present during
the initiation of all patient treatments involving the unit; and
6 CCR 1007-1 Part 7
Hazardous Materials and Waste Management Division

46
(2)
An authorized medical physicist and either an authorized user or an individual,
under the supervision of an authorized user, who has been trained to remove the
source applicator(s) in the event of an emergency involving the unit, to be
immediately available during continuation of all patient treatments involving the
unit.
7.52.6.2
For high dose-rate remote afterloader units, require:
(1)
An authorized user and an authorized medical physicist to be physically present
during the initiation of all patient treatments involving the unit; and
(2)
An authorized medical physicist and either an authorized user or a physician,
under the supervision of an authorized user, who has been trained in the
operation and emergency response for the unit, to be physically present during
continuation of all patient treatments involving the unit.
7.52.6.3
For gamma stereotactic radiosurgery units, require an authorized user and an
authorized medical physicist to be physically present throughout all patient treatments
involving the unit.
7.52.6.4
If a patient or research subject suffers a medical emergency during radiation
therapy:
(1)
Cease the therapy immediately;
(2)
Remove the source(s); and
(3)
Provide appropriate care to the patient or research subject.
7.52.6.5
If the patient expires during treatment, remove the source(s) before further
actions are taken.
7.52.6.6
Notify the RSO, or his or her designee, and an authorized user as soon as
possible, if the patient or human research subject has a medical emergency and,
immediately, if the patient dies.
7.52.7 A licensee shall have applicable emergency response equipm

[Text truncated at 120,000 characters. The full text is on the page linked above.]

## Nearby sections

- [6 CCR 1007-1 RADIATION CONTROL – (Rule Versions Prior to 04/01/2007)](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1.md)
- [6 CCR 1007-1 Part 01 RADIATION CONTROL - GENERAL PROVISIONS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_01.md)
- [6 CCR 1007-1 Part 02 RADIATION CONTROL - REGISTRATION OF RADIATION MACHINES, FACILITIES AND SERVICES](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_02.md)
- [6 CCR 1007-1 Part 03 RADIATION CONTROL - LICENSING OF RADIOACTIVE MATERIAL](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_03.md)
- [6 CCR 1007-1 Part 04 RADIATION CONTROL - STANDARDS FOR PROTECTION AGAINST RADIATION](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_04.md)
- [6 CCR 1007-1 Part 05 RADIATION CONTROL - RADIATION SAFETY REQUIREMENTS FOR INDUSTRIAL RADIOGRAPHIC OPERATIONS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_05.md)
- [6 CCR 1007-1 Part 06 RADIATION CONTROL - X-RAY IMAGING IN THE HEALING ARTS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_06.md)
- [6 CCR 1007-1 Part 07 RADIATION CONTROL - USE OF RADIONUCLIDES IN THE HEALING ARTS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_07.md)
- [6 CCR 1007-1 Part 08 RADIATION CONTROL - RADIATION SAFETY REQUIREMENTS FOR RADIATION GENERATING DEVICES NOT USED IN THE HEALING ARTS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_08.md)
- [6 CCR 1007-1 Part 09 RADIATION CONTROL - RADIATION SAFETY REQUIREMENTS FOR PARTICLE ACCELERATORS NOT USED IN THE HEALING ARTS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_09.md)
- [6 CCR 1007-1 Part 10 RADIATION CONTROL - NOTICES, INSTRUCTIONS, AND REPORTS TO WORKERS: INSPECTIONS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_10.md)
- [6 CCR 1007-1 Part 11 RADIATION CONTROL - SPECIAL LAND OWNERSHIP REQUIREMENTS GENERAL PROVISIONS](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_11.md)
- [6 CCR 1007-1 Part 12 RADIATION CONTROL - FEES FOR RADIATION CONTROL SERVICES](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_12.md)
- [6 CCR 1007-1 Part 13 RADIATION CONTROL - COMPLIANCE ENFORCEMENT](https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_13.md)

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/statutes/STATE_CO_CCR_6_CCR_1007_1_Part_07. Check the current official text before relying on it. Not legal advice.
